TOKYO, June 8 (Reuters) - Japan's stock index Nikkei changed
course and inched down on Tuesday, as losses in market
heavyweights offset gains in drugmakers after Eisai Co's
Alzheimer drug received U.S. nod.
Nikkei share average inched down 0.11% to 28,987.58
by 0235 GMT, while the broader Topix edged up 0.06% to
"The news on Eisai has given a boost to its peers as well as
the overall market," said Shoichi Arisawa, general manager of
the investment research department at IwaiCosmo Securities.
"Investors are also scooping up Japanese shares which lagged
behind their global peers as prospects of an economic recovery
has brightened amid a rollout of COVID-19 vaccines."
But Nikkei's earlier gains were snapped as investors were
cautious ahead of the U.S. consumer price index (CPI) report
this week and the U.S. central bank's meeting next week, market
U.S. regulators on Monday approved a drug jointly developed
by Eisai and Biogen Inc's as the first treatment to
attack a likely cause of Alzheimer's disease.
Drug makers were the top gainers among the Tokyo
Stock Exchange's 33 industry subindexes, with Eisai remaining
untraded as buy orders far exceeded sell orders.
Daiichi Sankyo jumped 4.58% and Astellas Pharma
Losses in index heavyweights, however, weighed on the
markets, with global start-up investor SoftBank Group
down 1.56% and air-conditioner maker Daikin Industries
Kawasaki Kisen Kaisha, up 5.38%, was the biggest
gainer on Nikkei, followed by Daiichi Sankyo.
Sumitomo Metal Mining , down 3.41%, was the largest
decliner on the index, followed by Oji Holdings losing
2.37% and Daikin Industries.
There were 130 advancers on the Nikkei index against 86
(Reporting by Junko Fujita; Editing by Rashmi Aich)